Who We Are

We are physicians and engineers dedicated to advancing neurocritical care. CranioView unites a diverse team of physicians, biomedical engineers, and medtech entrepreneurs to create life-saving solutions for patients with neurological injuries. Our flagship product is a wearable, noninvasive device that uses ocular ultrasound and machine learning to continuously monitor intracranial pressure (ICP) accurately and easily. By removing the risks of invasive procedures and overcoming the limitations of existing noninvasive tools, we enable clinicians to detect critical changes in brain physiology in real time. Our goal is to close the gap in ICP monitoring—whether at the bedside, on the battlefield, or in underserved areas—and improve outcomes for millions of patients worldwide. Founded at UCLA, CranioView has been recognized by multiple innovation programs for its transformative potential in digital health and critical care.

  • Co-Founder and Chief Executive Officer


    Gil Herrnstadt, PhD    , is a co-founder and CEO of CranioView, where he’s leading the product development and commercialization efforts. Gil’s career spans design and development at industry leaders and a broad research portfolio on the development of medical technology, as well as regulatory affairs experience. Gil’s expertise lies at the intersection of robotics and healthcare, focusing on wearable and diagnostic solutions to neurological and movement disorders.

  • Co-Founder and Chief Operating Officer

    I. Obi Emeruwa, MD, PhD, MBA, is an Assistant Clinical Professor in the Division of Pulmonary, Critical Care, and Sleep Medicine at the UCLA David Geffen School of Medicine. He regularly cares for patients with ICP issues in the medical intensive care unit and has a strong background in resource allocation in critical care and data analytics in healthcare. Obi is board-certified in pulmonary disease, critical care medicine, and internal medicine by the American Board of Internal Medicine (ABIM). He completed his internal medicine residency and chief residency at New York-Presbyterian Hospital/Columbia University Irving Medical Center (NYP/CUIMC). He earned his MD from the Columbia University College of Physicians and Surgeons, his MBA from Columbia Business School, and his PhD from the UCLA Fielding School of Public Health. Before entering medicine, he earned his bachelor’s degree in biomedical sciences and engineering from Harvard University.

  • Co-Founder and Chief Medical Officer

    Gabe Oland, MD, is an Assistant Clinical Professor of Surgery in the Garlock Division of General Surgery at the Mount Sinai Health System in New York, as well as the Director of Surgical Innovation and Artificial Intelligence in the Department of Artificial Intelligence. His clinical specialty is in minimally invasive general surgery, specifically bariatric and abdominal wall surgery. Gabe has always intertwined his passion for engineering with his practice in medicine. His research spans medical imaging, virtual nasal surgery software development with computational flow dynamics, COVID-19, and diverse topics in general surgery. Currently, he is researching how to utilize computer vision, a form of artificial intelligence that can interpret image and video data, to enhance surgeons' abilities in the operating room. As co-founder and CMO of CranioView, Gabe draws from his experience with ultrasound imaging, computer vision algorithm development, computer-aided design, and experience at the bedside caring for patients with neurological trauma in the surgical intensive care unit. His education and training include a BSE in biomedical engineering from Arizona State University, an MD from the medical school at the Medical College of Wisconsin, a general surgery residency at the University of California, Los Angeles, and a fellowship in minimally invasive and bariatric surgery at Mount Sinai.

  • Co-Founder and Chief Strategy Officer

    Neil Parikh, MD, MBA, is a Board-Certified Radiation Oncologist and Principal at HealthQuest Capital, a healthcare-focused growth-equity fund investing $20-50 million in innovative healthcare companies spanning medical devices, diagnostics, HCIT, digital health, and healthcare services.  Before moving to the buy-side in 2022, Neil treated genitourinary cancers at the San Antonio Cancer Center and published on value-based radiation oncology, PSMA-PET, and stereotactic body radiotherapy for prostate cancer. Earlier in his career, he spent two years with McKinsey & Company advising payors, providers, and life-science clients.  Neil holds a BA in Economics from Rice University, an MD from Baylor College of Medicine, and an MBA from Harvard Business School; he completed his Internal Medicine internship at Beth Israel Deaconess Medical Center and his Radiation Oncology residency at UCLA.

Where We’ve Been